	US 12,257,304 B2
	Systems targeting PSMA and CA9
Angela Boroughs, San Mateo, CA (US); Levi Gray-Rupp, Philadelphia, PA (US); Samuel A. Williams, Burlingame, CA (US); Zhen Jian Zhou, San Francisco, CA (US); Matthew Drever, Concord, CA (US); Duy Nguyen, San Diego, CA (US); Amy-Jo Casbon, San Francisco, CA (US); Anzhi Yao, San Francisco, CA (US); and Thomas Gardner, San Francisco, CA (US)
Assigned to Arsenal Biosciences, Inc., South San Francisco, CA (US)
Filed by Arsenal Biosciences, Inc., South San Francisco, CA (US)
Filed on Mar. 1, 2024, as Appl. No. 18/593,711.
Claims priority of provisional application 63/618,233, filed on Jan. 5, 2024.
Claims priority of provisional application 63/613,712, filed on Dec. 21, 2023.
Claims priority of provisional application 63/601,617, filed on Nov. 21, 2023.
Claims priority of provisional application 63/578,854, filed on Aug. 25, 2023.
Claims priority of provisional application 63/495,869, filed on Apr. 13, 2023.
Claims priority of provisional application 63/489,837, filed on Mar. 13, 2023.
Claims priority of provisional application 63/488,386, filed on Mar. 3, 2023.
Prior Publication US 2024/0342284 A1, Oct. 17, 2024
Int. Cl. A61P 35/00 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); C07K 16/40 (2006.01); C12N 5/10 (2006.01); C12N 9/22 (2006.01); C12N 15/00 (2006.01); C12N 15/11 (2006.01); C12N 15/12 (2006.01); C12N 15/62 (2006.01); C12N 15/79 (2006.01); C12N 15/90 (2006.01); C12N 5/078 (2010.01); C12N 15/63 (2006.01)

CPC A61K 39/464495 (2023.05) [A61K 39/4631 (2023.05); A61K 39/464454 (2023.05); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 16/3069 (2013.01); C07K 16/40 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 15/907 (2013.01); A61K 35/17 (2013.01); C07K 2317/31 (2013.01); C07K 2319/00 (2013.01); C12N 5/0634 (2013.01); C12N 5/10 (2013.01); C12N 15/00 (2013.01); C12N 15/62 (2013.01); C12N 15/63 (2013.01); C12N 2310/20 (2017.05)]

61 Claims

1. One or more nucleic acid(s) encoding a system comprising:

a. a first chimeric polypeptide comprising a priming receptor comprising a first extracellular antigen-binding domain that specifically binds Prostate-Specific Membrane Antigen (PSMA), wherein the first antigen-binding domain comprises a first variable heavy (VH) chain sequence comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3, of the VH sequence set forth in SEQ ID NO: 118, and a first variable light (VL) chain sequence comprising three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3, of the VL sequence set forth in SEQ ID NO: 119; and

b. a second chimeric polypeptide comprising a chimeric antigen receptor (CAR) comprising a second extracellular antigen-binding domain that specifically binds to Carbonic Anhydrase IX (CA9), wherein the second antigen-binding domain comprises a second variable heavy (VH) chain sequence comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3, of the VH sequence set forth in SEQ ID NO: 99, and a second variable light (VL) chain sequence comprising three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3, of the VL sequence set forth in SEQ ID NO: 100.